Panmure Liberum marks Oxford Biomedica (LSE:OXB) as a Buy, with a price target of 800p, in a note published in step with the UK gene therapy firm's Capital Markets Day (which happened today).
The stock market event showcases how Oxford Biomedica, the gene-therapy developer and contract manufacturer, differentiates commercially, the broker highlighted in a note.
OXB has pitched long-term guidance of £500m revenue by 2030 (a 24% CAGR 2025-2030), which analyst Dr Julie Simmonds beleives is achievable if the firm's existing products progress and the new customer pipeline converts as projected.
The Panmure analyst noted a mid-term guidance range of £344–£406m by 2028 (which for reference, at the mid-range would imply roughly a 30% compound annual growth rate, CAGR).
Simmonds, meanwhile, noted that the broker's 800p target, which compares to a market price of just over 600p, brings OXB into line with peers while explicitly excluding any premium for faster growth.
The broker suggests that, if management convinces investors on the guidance and pipeline conversion, the London-listed shares, which have traded sideways since the fading away of the EQT takeover interest, may begin to rerate.
